National survey of the technique of intravitreal triamcinolone injection in the United Kingdom

Eye

Volumn 21, Issue 4, 2007, Pages 480-486

  Anijeet, D R ^a   Hanson, R J ^a   Bhagey, J ^a   Bates, R A ^a  

^a STOKE MANDEVILLE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETAMETHASONE; CEFUROXIME; CHLORAMPHENICOL; DEXAMETHASONE; KETOROLAC; PREDNISOLONE ACETATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; TRIAMCINOLONE ACETONIDE;

ARTICLE; CLINICAL PRACTICE; CONSULTATION; DRUG ADMINISTRATION ROUTE; HUMAN; INTRAOCULAR PRESSURE; MEDICAL SPECIALIST; OPHTHALMOLOGY; POSTOPERATIVE CARE; PRESCRIPTION; QUESTIONNAIRE; SURGEON; UNITED KINGDOM;

EID: 34147128714     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702232     Document Type: Article

References (27)

1. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as an adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 2001; 132: 425-427.
2. Aiello PL, Brucker JA, Chang S, Cunningham Jr ET, D' Amico DJ, Flynn Jr HW et al. Evolving guidelines for intravitreous injections. Retina 2004; 53-S19.
3. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84: 1064-1067.
4. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131: 468-471.
5. Jonas JB, Hayler JK, Panda- Jonas S. Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graef Arch Clin Exp Ophthalmol 2001; 239: 464-465.
6. Greenberg PB, Marthidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002; 86: 247-248.
7. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular oedema: An optical coherence tomography study. Ophthalmology 2001; 108: 765-772.
8. Danis RP, Thomas A, Ciulla TA, Pratt LM, Anilekar W. Intravitreal triamcinolone acetonide in exudative age related macular degeneration. Retina 2000; 20: 244-250.
9. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2002; 109: 920-927.
10. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular oedema. Arch Ophthalmol 2003; 121(1): 57-61.
11. Hida T, Chandler D, Arena JE, Marchemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986; 101: 190-195.
12. Yeung CK, Chan KP, Chan CK, Pang CP, Lam DS. The cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol 2004; 48(3): 236-242.
13. Jonas JB, Degenring RF, Kreissig I. Intravitreal injection of triamcinolone for diffuse macular oedema - in reply. Arch Ophthalmol 2004; 122: 1086-1088.
14. Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG et al. Intravitreal injection of triamcinolone for diffuse macular oedema. Arch Ophthalmol 2004; 122: 1085-1086.
15. Young ML, Kaiser PK, Sears JE. Acute endophthalmitis following intravitreal triamcinolone acetonide injection (abstract). In: Program and Abstracts of the American Academy of Ophthalmology 2002 Meeting. Orlando, FL, October 20-23, 2002.
16. Sutter FK, Gilles MC. Psuedo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003; 87: 972-974.
17. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA et al. Non- infectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121: 1279-1282.
18. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003; 23(5): 686-691.
19. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003; 121: 1663-1664.
20. Moshfeghi AA, Scott IU, Flynn Jr HW, Puliafito CA. Psuedohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004; 138(3): 489-492.
21. Moshfegi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136: 791-796.
22. Gragoudas ES, Adamis AP, Cunnigham Jr ET, Feinsod M, Guyer DR et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 30; 351(27): 2805-2816.
23. Chen SDM, Mohammed Q, Bowling B, Patel CK. Vitreous wick syndrome - a potential cause of endophthalmitis after intravitreal injection of triamcinolone through the pars plana. Am J Ophthalmol 2004; 137 6): 1159-1160.
24. Ibarra MS, Hermel M, Prenner JL, Hassan TS et al. Longer-term outcomes of transconjunctival sutureless 25-gauge vitrectomy. Am J Ophthalmol 2005; 139(5): 831-836.
25. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W et al. Safety of intravitreal injection of triamcinolone. Arch Ophthalmol 2004; 122: 336-340.
26. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol 1999; 27: 431-432.
27. Jonas JB, Kreissig I, Degenring RF. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87: 24-27.